North America holds a prominent position in the connected diagnostics landscape, supported by well-developed healthcare systems and widespread acceptance of digital health tools. Across the U.S. and Canada, hospitals, labs, and home-care providers rely on cloud-linked diagnostic devices for earlier detection, remote patient monitoring, and quicker clinical decisions. Favorable regulations, a growing chronic disease burden, and a strong base of leading companies keep the regional market expanding.

Connected Diagnostics market size is expected to reach US$ 13.84 Billion by 2034 from US$ 5.63 Billion in 2025. The market is anticipated to register a CAGR of 10.51% during the forecast period 2026–2034.

What is driving the market?

Increasing prevalence of chronic and infectious diseases, demand for point-of-care (POC) decentralized testing, and the integration of artificial intelligence (AI) with electronic health records (EHR) serve as the primary growth drivers. Diagnostic manufacturers and healthcare systems are required to improve diagnostic accuracy, reduce laboratory turnaround times, and minimize operational costs. Hospitals, urgent care centers, and home-care providers are actively adopting connected diagnostic devices that safely store, analyze, and transmit patient data without compromising data security or regulatory compliance.

The transition is moving beyond isolated testing hardware toward fully connected digital ecosystems. Suppliers are investing in Bluetooth- and Wi-Fi-enabled analyzers, cloud-based laboratory information management systems (LIMS), portable point-of-care devices, and telemetry-integrated diagnostic systems. Cybersecurity vulnerabilities, high initial deployment costs, and interoperability challenges between legacy hospital IT systems and new connected diagnostic equipment remain key constraints.

Download Sample Report@ https://www.theinsightpartners.com/sample/TIPRE00015772

Which region leads?

North America leads the market, accounting for an estimated 36%–40% share in 2025. Growth is supported by advanced healthcare infrastructure, high adoption of digital health solutions, early regulatory integration of telemetry and remote diagnostics, and major investments from leading medical technology players.

Asia Pacific is the fastest-growing region, with a projected CAGR of 14.8%–15.6% during the forecast period. Rapid urbanization, expanding healthcare access, growing prevalence of chronic lifestyle diseases, and heavy investments in telemedicine and digital health infrastructure drive market expansion. China and India present significant long-term opportunities as growing patient populations coincide with national initiatives to modernize healthcare delivery and rural diagnostic accessibility.

Europe holds an estimated 27%–31% market share, supported by stringent quality standards, widespread adoption of centralized EHR frameworks, and strong government support for digital pathology and remote patient care.

Which segment leads?

By product type, Connected In-Vitro Diagnostics (IVD) Devices & Analyzers leads the material/product category, representing an estimated 42%–46% of market revenue in 2025. Its dominant position is driven by high testing volumes across clinical laboratories and blood banks, continuous demand for automated pathology, and rapid integration of IoT communication modules into laboratory equipment.

By end-use industry, Hospitals & Reference Laboratories leads with an estimated 43%–47% share in 2025, reflecting high patient volume, complex diagnostic testing workflows, and early adoption of automated connected infrastructure. Point-of-Care & Home Healthcare is identified as the fastest-growing end-user segment, with an estimated CAGR of 15.2%–16.1%, propelled by the adoption of wearable diagnostic monitors, connected blood glucose meters, and mobile health applications.

Which companies are prominent?

The report identifies Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Danaher Corporation, Thermo Fisher Scientific, BD (Becton, Dickinson and Company), Sysmex Corporation, bioMérieux, Hologic, Inc., and Quest Diagnostics as prominent market participants.

These companies compete across cloud-enabled diagnostic hardware, clinical decision support software, AI diagnostic algorithms, point-of-care testing systems, and laboratory automation. Strategic differentiation increasingly depends on data interoperability, cloud security certifications, real-time analytics capabilities, and seamless integration with existing hospital workflow environments.

What is changing in 2026?

The market is shifting from basic connected hardware toward intelligent, compliance-ready, end-to-end diagnostic ecosystems. Diagnostic requirements increasingly demand real-time data transmission, cloud-based remote maintenance, predictive equipment diagnostics, automated quality control tracking, and strict cybersecurity compliance under evolving health data privacy laws.

Manufacturers are accelerating the development of AI-assisted diagnostic platforms, ultra-portable handheld connected analyzers, and cloud-native laboratory middleware. Healthcare procurement decisions are tightly linked to proof of interoperability, cyber resilience, data accuracy, and workflow time savings, driving multi-year technology partnerships between medical device manufacturers, cloud providers, and health networks.

What are the major investment opportunities?

The strongest opportunities lie in cloud-integrated point-of-care testing platforms, AI-driven diagnostic software, secure healthcare IoT architecture, and decentralized diagnostic networks. Investment in cloud connectivity, cybersecurity framework integration, and mobile edge computing can significantly reduce diagnostic lag and streamline clinical workflows.

Additional opportunities include:

• Multiplex point-of-care testing kits with automated telemetry output.
• AI-assisted pathology and imaging software for automated disease detection.
• Remote diagnostic subscriptions and Software-as-a-Service (SaaS) models that provide healthcare facilities with recurring, scalable analytical capabilities.

Asia Pacific offers high-yield expansion potential due to rapid healthcare modernization and government-backed remote care initiatives. Investors should prioritize technology vendors that combine high diagnostic specificity, robust data encryption, regulatory approval readiness, and seamless compatibility with regional hospital information systems.

About The Insight Partners

The Insight Partners is a leading market research and consulting firm delivering actionable insights through in-depth industry analysis and strategic intelligence. The firm supports clients across various industries in making informed decisions by providing comprehensive market forecasts, competitive assessments, and growth opportunities.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Ankit Mathur

E-mail: sales@theinsightpartners.com

Phone: +1-646-491-9876

Related Reports:

Business Card Software Market Growth Drivers and Forecast by 2031

Business Plan Software Market Growth Drivers and Forecast by 2027

Calibration Management Software Market Size, Trends & Growth by 2034

Also Available in : KoreanGermanJapaneseFrenchChineseItalianSpanish